TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

Amgen (AMGN) and AstraZeneca reported positive phase 3 trial results for Tezspire (tezepelumab) in treating eosinophilic esophagitis, showing significant remission and symptom improvement. Amgen has a 2.3% dividend yield, a 56% payout ratio, and a 7.1% 3-year dividend growth rate. The company's GF Score is 85/100, indicating strong financial health. Insiders have sold $29.3M in shares over the past year, while 12 gurus hold AMGN with slight net trimming.

Amgen and AstraZeneca reported phase 3 trial results for Tezspire in eosinophilic esophagitis, showing histologic remission in most patients and reduced swallowing difficulties. The CROSSING trial evaluated Tezspire 210 mg.

Amgen (AMGN) and AstraZeneca (AZN) reported Phase III trial results for Tezspire in eosinophilic esophagitis, showing 68.9% of patients achieved histologic remission at 24 weeks, compared to 3.5% on placebo. The data, presented at UEG Week 2026, suggests potential for a new indication.

Amgen and AstraZeneca reported positive phase 3 trial results for Tezspire in treating eosinophilic esophagitis (EoE). The drug showed significant improvements in histologic remission and dysphagia symptoms. Amgen shares rose 2.4% and AstraZeneca shares increased 0.9%.

AstraZeneca (AZN) and Amgen (AMGN) reported that Tezspire met primary and secondary endpoints in a Phase 3 trial for eosinophilic esophagitis, showing sustained improvements at week 52. The drug's safety profile was consistent with approved uses. AZN and AMGN shares rose 2.24% and 2.29%, respectively.

Amgen and AstraZeneca reported positive results from a Phase 3 study of Tezspire, showing improvement in eosinophilic esophagitis. The companies celebrated the trial outcomes, which may impact their future earnings and drug pipeline valuations.